Magle Chemoswed

SOLID REVENUES WITH INCREASED RETURNS

OCTOBER – DECEMBER 2022

• Net sales amounted to 45.9 MSEK (35.9)
• EBITDA equalled 5.9 MSEK (4.4)
• Operating profit (EBIT) is 2.9 MSEK (1.3)
• Profit after tax amounted to 0.8 MSEK (1.2)
• Earnings per share SEK 0.1 (0.1) per share

JANUARY – DECEMBER 2022

• Net sales amounted to 145.7 MSEK (132.1)
• EBITDA equalled 25.5 MSEK (16.8).
• Operating profit (EBIT) is 12.5 MSEK (5.2)
• Profit after tax amounted to 9.4 MSEK (4.2)
• Earnings per share SEK 0.9 (0.4) per share

Justin Pierce, CEO of Magle Chemoswed Holding AB, commented, “Looking back at the year 2022, we can conclude that Magle Group has made significant progress in the efforts of generating steadily growing revenues and profit based on its DSM (Degradable Starch Microsphere) material science platform and state-of-the-art CDMO business.”

EVENTS DURING THE REPORTING PERIOD

• AXXO Woundgel launched in Kuwait
• EmboCept® S registered in Argentina
• SmartPAN® ViP study completed

EVENTS AFTER THE REPORTING PERIOD

• Investment to expand CDMO fill and finish production capabilities has commenced in Q1, 2023

The full report can be downloaded at https://maglegroup.com/financial-reports/